|
Monalizumab Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: IPH-2201, IPH2201, Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody, NN-8765, NN8765 +1 more
Pipeline
Phase 2: 3
Top Sponsors
- SWOG Cancer Research Network1
- John Sfakianos1
- AstraZeneca1
Indications
- Cancer3
- Lung Cancer2
- Lung Small Cell Carcinoma, P Subtype1
- Lung Small Cell Carcinoma, N Subtype1
- Lung Small Cell Carcinoma, I Subtype1
Little Rock, Arkansas1 trial
Phase 2
Newark, Delaware1 trial
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Helen F Graham Cancer Center
Phase 2
Tampa, Florida1 trial
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Moffitt Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.